October 25, 2017 (View All Issues)
Smashing the Glass Ceiling in Medicine
Error loading Partial View script (file: ~/Views/MacroPartials/TAP Article Portrait Widget.cshtml) Error loading Partial View script (file: ~/Views/MacroPartials/TAP Article Portrait Widget.cshtml)
IT IS A SAD TRUTH that academic medicine, like many other professions, has a glass ceiling that...
Second-Line Pembrolizumab Extends Survival in Urothelial Cancer
Error loading Partial View script (file: ~/Views/MacroPartials/TAP Article Portrait Widget.cshtml)
PEMBROLIZUMAB (KEYTRUDA) extended survival by about 3 months in patients with advanced urothelial cancer whose disease progressed on platinum-based chemotherapy vs investigator’s choice of therapy,...
Could the Rising Rates of Colorectal Cancer in AYAs Be Linked to HPV Infection?
Error loading Partial View script (file: ~/Views/MacroPartials/TAP Article Portrait Widget.cshtml)
TWO STUDIES published this year examining the incidence of colorectal cancer in adolescents and young adults (AYAs) show an undeniable and sobering trend: Colorectal cancer rates are increasing in...
Consolidative Radiation Therapy: New Paradigm for Limited Metastatic NSCLC?
Error loading Partial View script (file: ~/Views/MacroPartials/TAP Article Portrait Widget.cshtml)
ADDING CONSOLIDATIVE RADIATION therapy to maintenance chemotherapy had a robust effect on preventing disease progression compared with maintenance chemotherapy alone in patients with limited...
Immunotherapy Plus Radiation Appears Active in Patients With Solid Tumors and Lung or Liver Metastases
Error loading Partial View script (file: ~/Views/MacroPartials/TAP Article Portrait Widget.cshtml)
THE NOVEL COMBINATION of immunotherapy with ipilimumab (Yervoy) plus radiation achieved a clinical benefit in up to 57% of patients with solid tumors and metastases to the lungs or liver, according...
Cutting Radiation Exposure by 50% Appears Safe and Effective in HPV-Positive Head and Neck Cancer
Error loading Partial View script (file: ~/Views/MacroPartials/TAP Article Portrait and Quote.cshtml)
AGGRESSIVE REDUCTION in radiation therapy appears to be a potential win-win situation for patients with human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma, according to...
Expert Point of View: Paul Harari, MD
Error loading Partial View script (file: ~/Views/MacroPartials/TAP Article Portrait Widget.cshtml)
COMMENTING ON THIS STUDY, ASTRO President Paul Harari, MD, was enthusiastic about the results. Dr. Harari is the Jack Fowler Professor and Chairman of the Department of Human Oncology at the...
ASTRO Names Recipients of Junior Faculty, Resident/Fellow Awards at Annual Meeting
THE AMERICAN SOCIETY FOR RADIATION ONCOLOGY (ASTRO) has awarded $275,000 in research awards to four early-career scientists as part of the Society’s efforts to retain and foster the intellectual research talent currently entering the field of radiation oncology. For 2017, the Research Grants...
Positive Early Data on Second-Line Ramucirumab/Docetaxel in Platinum-Refractory Advanced Urothelial Cancer
Error loading Partial View script (file: ~/Views/MacroPartials/TAP Article Portrait and Quote.cshtml)
RAMUCIRUMAB (CYRAMZA) added to docetaxel improved progression-free survival and almost doubled the overall response rate compared with docetaxel alone in patients with advanced or metastatic...
ASCO Chief Medical Officer Scheduled to Speak at ECRI Annual Conference
Error loading Partial View script (file: ~/Views/MacroPartials/TAP Article Portrait Widget.cshtml)
ASCO SENIOR VICE PRESIDENT and Chief Medical Officer, Richard L. Schilsky, MD, FACP, FASCO, FSCT, will participate in a panel discussion at the ECRI Annual Conference "Workflow, Workarounds, and...
ASCO Recognizes New Jersey Representative Leonard Lance With Congressional Leadership Award
Error loading Partial View script (file: ~/Views/MacroPartials/TAP Article Portrait Widget.cshtml)
ASCO HAS PRESENTED Representative Leonard Lance, of New Jersey’s 7th district, with its second annual Congressional Leadership Award in recognition of the lawmaker’s exceptional commitment to...
Patient-Physician Communication and Quality of Life Featured at 2017 Palliative and Supportive Care in Oncology Symposium
NEW RESEARCH examining patient-physician communication, yoga as supportive care, and psychosocial support for people with cancer will be featured at the 2017 Palliative and Supportive Care in Oncology Symposium on October 27–28, 2017, in San Diego. Featured sessions include randomized trials on...
Abiraterone or Docetaxel: Which Is Optimal for Hormone-Sensitive High-Risk Prostate Cancer?
ABIRATERONE ACETATE (Zytiga) plus prednisone and docetaxel have moved up from the castrate-resistant metastatic setting to earlier in the course of disease as treatment of high-risk hormone-sensitive prostate cancer in men who are initiating androgen-deprivation therapy, based on level 1 evidence...
Alectinib Yields Favorable Results in Phase III Trials of ALK-Positive NSCLC
RESULTS OF TWO separate phase III trials confirm the activity of alectinib (Alecensa) in the central nervous system (CNS) in patients with anaplastic lymphoma kinase (ALK)-positive non–small cell lung cancer (NSCLC). Results lend support for alectinib as the better first-line treatment option over...
Adjuvant BRAF/MEK Inhibition Improves Survival in Resectable Melanoma
FOR PATIENTS with locally advanced, resectable melanoma harboring BRAF mutations, adjuvant treatment with BRAF/ MEK inhibition significantly improves overall survival, results of the COMBI-AD trial have shown. The study was presented at the European Society for Medical Oncology (ESMO) 2017...
CheckMate 238: Nivolumab Shows Benefit as Adjuvant Melanoma Treatment
IN THE TREATMENT of malignant melanoma, immune checkpoint inhibitors are no longer just for metastatic disease, and the best type may be agents targeting the programmed cell death protein 1 (PD-1), according to results of CheckMate 238, presented at the European Society for Medical Oncology (ESMO)...
Expert Point of View: Alexander Eggermont, MD, PhD
Error loading Partial View script (file: ~/Views/MacroPartials/TAP Article Portrait Widget.cshtml)
BASED ON THE RESULTS of COMBI-AD1 and CheckMate 238,2 invited discussant Alexander Eggermont, MD, PhD, Professor of Oncology at Gustave Roussy in Paris, commented: “It’s a good day for melanoma!”
...
Standard of Care Upheld for Locally Advanced Cervical Cancer
Error loading Partial View script (file: ~/Views/MacroPartials/TAP Article Portrait and Quote.cshtml)
THE FIRST FORMAL comparison of two acceptable approaches to locally advanced cervical cancer has concluded that standard chemoradiotherapy is preferable to neoadjuvant chemotherapy plus surgery....
FDA Conducts Global Operation to Protect Consumers From Potentially Dangerous Prescription Drugs Sold Online
Error loading Partial View script (file: ~/Views/MacroPartials/TAP Article Portrait Widget.cshtml)
THE U.S. FOOD AND DRUG ADMINISTRATION (FDA), in partnership with international regulatory and law enforcement agencies, recently took action against more than 500 websites that illegally sell...
Nivolumab/Ipilimumab in Patients With Advanced Melanoma Who Did or Did Not Discontinue Induction Treatment due to Adverse Events
Error loading Partial View script (file: ~/Views/MacroPartials/TAP Article Portrait and Quote.cshtml)
IN A RETROSPECTIVE pooled analysis of the CheckMate 069 and 067 studies reported in the Journal of Clinical Oncology, Dirk Schadendorf, MD, of the University Hospital Essen and the German Cancer...
ASCO Clinical Practice Guideline Update on Antiemetics in Patients With Cancer
Error loading Partial View script (file: ~/Views/MacroPartials/TAP Article Portrait Widget.cshtml) Error loading Partial View script (file: ~/Views/MacroPartials/TAP Article Portrait Widget.cshtml)
AS REPORTED BY Paul J. Hesketh, MD, of Lahey Hospital and Medical Center, Burlington,...
Phase III Trial Shows No Survival Benefit to Adding First-Line Ipilimumab to Chemotherapy in Advanced Squamous NSCLC
Error loading Partial View script (file: ~/Views/MacroPartials/TAP Article Portrait Widget.cshtml)
IN A PHASE III trial reported by Ramaswamy Govindan, MD, of Washington University School of Medicine, and colleagues in the Journal of Clinical Oncology, the addition of first-line ipilimumab...
No Progression-Free Survival Benefit With First-Line Nivolumab vs Chemotherapy in Advanced PD-L1–Positive NSCLC
Error loading Partial View script (file: ~/Views/MacroPartials/TAP Article Portrait Widget.cshtml)
AS REPORTED BY David P. Carbone, MD, PhD, of The Ohio State University Comprehensive Cancer Center, Columbus, and colleagues in The New England Journal of Medicine, the phase III CheckMate 026 trial...
Regional Radiation Therapy Reduces Risk of Regional Recurrence in Node-Positive Cutaneous Melanoma
Error loading Partial View script (file: ~/Views/MacroPartials/TAP Article Portrait Widget.cshtml) Error loading Partial View script (file: ~/Views/MacroPartials/TAP Article Portrait Widget.cshtml) Error loading Partial View script (file: ~/Views/MacroPartials/TAP Article Portrait Widget.cshtml) ...
Carfilzomib Improves Overall Survival vs Bortezomib in Relapsed/Refractory Multiple Myeloma
Error loading Partial View script (file: ~/Views/MacroPartials/TAP Article Portrait and Quote.cshtml)
AT A PRESPECIFIED interim analysis, the phase III ENDEAVOR trial has shown a significant overall survival benefit for carfilzomib (Kyprolis) vs bortezomib (Velcade) in patients with...
Carfilzomib May Be a Strong Candidate for Salvage Therapy in Relapsed/Refractory Multiple Myeloma—but Questions Remain
Error loading Partial View script (file: ~/Views/MacroPartials/TAP Article Portrait and Quote.cshtml)
WITH THE INCLUSION of proteasome inhibitors and immunomodulatory agents first into salvage and then as components of first-line, consolidation, and maintenance regimens, response rates, depth of...
FDA Awards Grants for Clinical Trials to Stimulate Product Development for Rare Diseases
THE U.S. FOOD and Drug Administration (FDA) has awarded numerous new clinical trial research grants, totaling more than $22 million over the next 4 years, to boost the development of products for patients with rare diseases. These new grants were awarded to principal investigators from academia and ...
ASCO University Offers New Course Covering Resource-Stratified Guidelines
ASCO has created a series of clinical practice guidelines to benefit clinicians, public health leaders, and policymakers in all resource settings. These resource-stratified guidelines help medical professionals outline appropriate methods of treatment and care based on the level of health-care...
Funding the Future of Cancer Research Led by Women Making an Impact
WOMEN WHO CONQUER CANCER (WWCC) funds the promising careers of the best and brightest women researchers through the Conquer Cancer Foundation’s Young Investigator Award (YIA) program. Thanks to the generosity of supporters, five awards were granted in 2017. Right now, gifts to the WWCC Endowment...
Documentary Film Takes a Walk on the Wild Side With Oncology Pioneers
Error loading Partial View script (file: ~/Views/MacroPartials/TAP Article Portrait Widget.cshtml) Error loading Partial View script (file: ~/Views/MacroPartials/TAP Article Portrait Widget.cshtml) Error loading Partial View script (file: ~/Views/MacroPartials/TAP Article Portrait Widget.cshtml) ...
Recommend an Early-Career Oncologist for ASCO’s 2018 Health Policy Fellowship
APPLICATIONS ARE now being accepted for ASCO’s 2018 Health Policy Fellowship program. The Health Policy Fellowship aims to provide oncology fellows and early-career physicians with the necessary skills to shape cancer policy and to help increase the involvement of ASCO members in policy, advocacy,...
Quality Training Program Now Accepting Applications for 2018; Courses to Be Held in Miami and Northern Virginia
Applications are now being accepted for ASCO’s Quality Training Program (QTP), a comprehensive program designed to train oncology health-care providers to investigate and implement data-driven quality improvement, as well as manage clinical and nonclinical processes and outcomes.
The program...
For Your Patients: ASCO Answers Managing Cancer-Related Pain Booklet
Error loading Partial View script (file: ~/Views/MacroPartials/TAP Article Image Widget.cshtml)
ASCO’S BOOKLET on Managing Cancer-Related Pain helps you work together with your patients to develop an individualized plan for pain management before they start treatment. Patients and their caregivers ...
Register for December 1 FDA Workshop on Cardiovascular Toxicities in Immunotherapy Trials
THE U.S. FOOD & DRUG ADMINISTRATION (FDA) and the Oncology Center of Excellence (OCE) will host a complimentary public workshop, Assessment of Cardiovascular Toxicities in Immuno-Oncology Trials, on December 1. ASCO is supporting the workshop with the American College of Cardiology (ACC), the...
ASCO Guideline on Stage IV NSCLC Therapy Updated
Error loading Partial View script (file: ~/Views/MacroPartials/TAP Article Portrait Widget.cshtml) Error loading Partial View script (file: ~/Views/MacroPartials/TAP Article Portrait Widget.cshtml)
An update of the ASCO clinical practice guideline on the systemic treatment of patients with stage...
Stand Up To Cancer Catalyst Launches 10 Clinical Trial Projects
Stand Up To Cancer has awarded 10 Stand Up To Cancer Catalyst clinical trial projects in which researchers from more than 30 institutions collaborate across academic and corporate borders on clinical trials studying correlated translational research. The inaugural Stand Up To Cancer Catalyst...
Engaging Patients in Value-Based Care
Error loading Partial View script (file: ~/Views/MacroPartials/TAP Article Portrait Widget.cshtml) Error loading Partial View script (file: ~/Views/MacroPartials/TAP Article Portrait Widget.cshtml)
Turning the Tide Against Cancer is an annual conference sponsored by the Personalized Medicine...
Melatonin
Error loading Partial View script (file: ~/Views/MacroPartials/TAP Article Image Widget 2.cshtml)
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies commonly used by patients with cancer....
Chronicling a Family’s History of Cancer
Error loading Partial View script (file: ~/Views/MacroPartials/TAP Article Image Widget 2.cshtml)
Cancer has been an intimate part of Nancy Borowick’s life since her mother, Laurel, was diagnosed with breast cancer in 1997, when Nancy was 12. She began photographing her mother’s journey with the...
Early Love of Science and Famous Mentor Paved the Way for Gwen L. Nichols, MD, in Hematologic Cancer
Nationally regarded leukemia and lymphoma specialist Gwen L. Nichols, MD, was born in the Bronx, New York, and when she became of school age, her parents moved to the upstate suburb of Chappaqua, where she grew up. Asked if there were any physicians in her family who might have influenced her...
Magee-Womens Research Institute Announces 2018 Women’s Health Award
Error loading Partial View script (file: ~/Views/MacroPartials/TAP Article Portrait Widget.cshtml) Error loading Partial View script (file: ~/Views/MacroPartials/TAP Article Portrait Widget.cshtml)
To advance ongoing and innovative research in women’s health, a $1 million prize will be awarded to ...
Four Pitt Researchers Receive American Cancer Society Grants
Four cancer researchers from the University of Pittsburgh will share $882,000 in grants recently awarded by the American Cancer Society (ACS) as part of a $45 million funding program.
Sarah M. Belcher, BSN, of Pitt’s Department of Health and Community Systems, will further her research on patients ...
23 ASTRO Members Awarded Fellows Designation
The American Society for Radiation Oncology (ASTRO) has selected 23 distinguished members to receive the ASTRO Fellow designation. The 2017 class of Fellows was recognized during the Awards Ceremony at ASTRO’s 59th Annual Meeting, which was held September 24–27 in San Diego.
The Fellows Program,...
Stalked by BRCA1: A Women Struggles to Survive the Same Disease That Killed Her Mother
Error loading Partial View script (file: ~/Views/MacroPartials/TAP Article Image Widget 2.cshtml)
No matter what a person does in life, for good and bad, his or her inherited genetic makeup follows along the way. Such was the case with British journalist Sarah Gabriel, who inherited the BRCA1...
Breast Cancer Has Changed Me, But the Change Has Been Positive
I’ve always had dense breasts and avoided doing breast self-exams because I couldn’t tell if the lumpiness I was feeling was something serious or merely normal fibrous tissue. Instead I relied on my yearly mammogram to spot any early signs of cancer. Four years ago, I was once again relieved to...
Howard A. Fine, MD, Wins NIH Director’s Pioneer Award
Error loading Partial View script (file: ~/Views/MacroPartials/TAP Article Portrait Widget.cshtml)
Neuro-oncologist Howard A. Fine, MD, of Weill Cornell Medicine and NewYork-Presbyterian, will receive a 5-year, $6 million National Institutes of Health (NIH) Director’s Pioneer Award for brain...
Julie R. Palmer, ScD, Honored With 2017 AACR Distinguished Lecture on Cancer Health Disparities
Error loading Partial View script (file: ~/Views/MacroPartials/TAP Article Portrait Widget.cshtml)
The American Association for Cancer Research (AACR) awarded Julie R. Palmer, ScD, the AACR Distinguished Lecture on the Science of Cancer Health Disparities, funded by Susan G. Komen. Dr. Palmer was...
Edward E. Partridge, MD, Named Chief Medical Officer of Guideway Care
Error loading Partial View script (file: ~/Views/MacroPartials/TAP Article Portrait Widget.cshtml)
Edward E. Partridge, MD, has been named Chief Medical Officer of the Birmingham, Alabama–based Guideway Care, according to an announcement by Craig Parker, the company’s President and Chief Executive ...
Nivolumab Treatment Beyond Disease Progression in Advanced Melanoma
Error loading Partial View script (file: ~/Views/MacroPartials/TAP Article Portrait Widget.cshtml)
In a retrospective analysis reported in JAMA Oncology, Georgina V. Long, MBBS, PhD, of the Melanoma Institute Australia, North Sydney, and colleagues found that a substantial proportion of patients...
Tremelimumab in Previously Treated Advanced Malignant Mesothelioma
Error loading Partial View script (file: ~/Views/MacroPartials/TAP Article Portrait Widget.cshtml)
In the randomized phase IIB DETERMINE trial, the cytotoxic T-lymphocyte–associated protein 4 (CTLA-4) inhibitor tremelimumab did not improve overall survival vs placebo as second- or third-line...
For HPV Vaccine to Have Optimal Impact, ‘Provider Hesitancy’ Must Be Overcome
Honoring National Cancer Institute researchers Douglas R. Lowy, MD, and John T. Schiller, PhD, with the Lasker-DeBakey Clinical Medical Research Award for advances in technology that enabled the development of human papillomavirus (HPV) vaccines to prevent cervical cancer and other tumors caused by ...
Leading Lymphoma Clinician, Researcher, and Mentor, Oliver ‘Ollie’ Press, MD, PhD, Dies at 65
Error loading Partial View script (file: ~/Views/MacroPartials/TAP Article Portrait Widget.cshtml)
In 1988, 38-year-old Rita Lawrence found herself in a desperate situation. The lymphoma she’d been battling had recurred after 2 years of remission. She’d endured multiple rounds of tough...
Moffitt Cancer Center Holds Leadership Series in New York
Moffitt Cancer Center has made a lasting commitment to the prevention and cure of cancer, working fervently in the areas of patient care, research, and education to advance further in fighting this disease, according to Alan F. List, MD, Moffitt’s President and Chief Executive Officer. Dr. List,...
Erratum: Adoptive Cell Therapy—Act 1: The Beginning
In the September 25, 2017, issue of The ASCO Post, page 1, the date of approval was cited incorrectly for the genetically engineered T-cell therapy tisagenlecleucel (Kymriah). The U.S. Food and Drug Administration approved tisagenlecleucel on August 30, 2017. The T-cell therapeutic is approved for...
